TABLE 2.
Antiviral effects of oral TDF administration on hepatic WHV replicative intermediates and WHV RNA in woodchucks chronically infected with WHV
| Treatment and time | Mean RI (pg/μg of total cell DNA)a | Mean RNA (pg/μg of total cell RNA) |
|---|---|---|
| Control (placebo) | ||
| Pretreatment (wk −2) | 1,820 ± 403 (1,600-2,500) | 55 ± 12 (56-83) |
| End of treatment (wk 4) | 1,361 ± 594 (1,000-2,400) | 59 ± 20 (50-92) |
| 4 wk posttreatment (wk 8) | 1,975 ± 171 (1,800-2,200) | 81 ± 11 (68-91) |
| 12 wk posttreatment (wk 16) | 1,725 ± 403 (1,400-2,300) | 77 ± 15 (60-95) |
| TDF (0.5 mg/kg/day) | ||
| Pretreatment (wk −2) | 1,825 ± 670 (1,300-2,800) | 78 ± 14 (62-96) |
| End of treatment (wk 4) | 2,075 ± 479 (1,500-2,600) | 75 ± 14 (54-85) |
| 4 wk posttreatment (wk 8) | 2,425 ± 359 (1,900-2,700) | 79 ± 10 (69-93) |
| 12 wk posttreatment (wk 16) | 2,100 ± 216 (1,800-2,300) | 75 ± 12 (60-88) |
| TDF (1.5 mg/kg/day) | ||
| Pretreatment (wk −2) | 1,450 ± 311 (1,200-1,900) | 66 ± 7 (56-72) |
| End of treatment (wk 4) | 1,725 ± 618 (1,000-2,500) | 73 ± 13 (60-88) |
| 4 wk posttreatment (wk 8) | 1,275 ± 275 (1,000-1,600)b | 69 ± 14 (54-81) |
| 12 wk posttreatment (wk 16) | 1,550 ± 265 (1,200-1,800) | 77 ± 11 (67-92) |
| TDF (5.0 mg/kg/day) | ||
| Pretreatment (wk −2) | 2,200 ± 627 (1,400-2,900) | 75 ± 18 (55-94) |
| End of treatment (wk 4) | 1,705 ± 765 (620-2,400) | 73 ± 16 (52-89) |
| 4 wk posttreatment (wk 8) | 2,325 ± 340 (2,000-2,800) | 80 ± 7 (71-87) |
| 12 wk posttreatment (wk 16) | 2,075 ± 330 (1,700-2,400) | 66 ± 10 (56-78) |
| TDF (15.0 mg/kg/day) | ||
| Pretreatment (wk −2) | 1,975 ± 457 (1,300-2,300) | 62 ± 8 (51-70) |
| End of treatment (wk 4) | 1,638 ± 844 (550-2,400) | 71 ± 7 (63-80) |
| 4 wk posttreatment (wk 8) | 1,425 ± 457 (1,100-2,100) | 72 ± 11 (56-80) |
| 12 wk posttreatment (wk 16) | 1,875 ± 171 (1,700-2,100) | 74 ± 15 (55-90) |
a
There were four woodchucks in each group. Values are means ± standard deviations, and overall ranges of values for WHV nucleic acids are presented in parentheses. Concentrations of hepatic intracellular WHV DNA replicative intermediates (RI) and total WHV RNA were normalized for total cellular DNA or RNA by using the relative levels of β-actin DNA or RNA (β-actin hybridization probe purchased from Oncor, Inc., Gaithersburg, MD).
b
Difference from placebo control group is statistically significant, P < 0.01.